These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 29253458)

  • 1. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Greuter MJE; Coupé VMH; Canfell K
    Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1450-1461. PubMed ID: 30190276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
    Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
    Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data.
    Tran B; Keating CL; Ananda SS; Kosmider S; Jones I; Croxford M; Field KM; Carter RC; Gibbs P
    Intern Med J; 2012 Jul; 42(7):794-800. PubMed ID: 21883782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
    Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
    Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
    Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
    J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
    McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
    Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History, development and future of cancer screening in Australia.
    Olver IN; Roder D
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.
    Sharp L; Tilson L; Whyte S; Ceilleachair AO; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
    BMC Health Serv Res; 2013 Mar; 13():105. PubMed ID: 23510135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.
    He E; Lew JB; Egger S; Banks E; Ward RL; Beral V; Canfell K
    Prev Med; 2018 Jan; 106():185-193. PubMed ID: 29109015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
    Pil L; Fobelets M; Putman K; Trybou J; Annemans L
    Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.